Skip to main content
PMC home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1998 Feb;7(2):300–305. doi: 10.1002/pro.5560070209

Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant.

L Hong 1, J A Hartsuck 1, S Foundling 1, J Ermolieff 1, J Tang 1
PMCID: PMC2143907  PMID: 9521105

Abstract

The mutation Ala28 to serine in human immunodeficiency virus, type 1, (HIV-1) protease introduces putative hydrogen bonds to each active-site carboxyl group. These hydrogen bonds are ubiquitous in pepsin-like eukaryotic aspartic proteases. In order to understand the significance of this difference between HIV-1 protease and homologous, eukaryotic aspartic proteases, we solved the three-dimensional structure of A28S mutant HIV-1 protease in complex with a peptidic inhibitor U-89360E. The structure has been determined to 2.0 A resolution with an R factor of 0.194. Comparison of the mutant enzyme structure with that of the wild-type HIV-1 protease bound to the same inhibitor (Hong L, Treharne A, Hartsuck JA, Foundling S, Tang J, 1996, Biochemistry 35:10627-10633) revealed double occupancy for the Ser28 hydroxyl group, which forms a hydrogen bond either to one of the oxygen atoms of the active-site carboxyl or to the carbonyl oxygen of Asp30. We also observed marked changes in orientation of the Asp25 catalytic carboxyl groups, presumably caused by the new hydrogen bonds. These observations suggest that catalytic aspartyl groups of HIV-1 protease have significant conformational flexibility unseen in eukaryotic aspartic proteases. This difference may provide an explanation for some unique catalytic properties of HIV-1 protease.

Full Text

The Full Text of this article is available as a PDF (5.3 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cooper J. B., Khan G., Taylor G., Tickle I. J., Blundell T. L. X-ray analyses of aspartic proteinases. II. Three-dimensional structure of the hexagonal crystal form of porcine pepsin at 2.3 A resolution. J Mol Biol. 1990 Jul 5;214(1):199–222. doi: 10.1016/0022-2836(90)90156-G. [DOI] [PubMed] [Google Scholar]
  2. Davies D. R. The structure and function of the aspartic proteinases. Annu Rev Biophys Biophys Chem. 1990;19:189–215. doi: 10.1146/annurev.bb.19.060190.001201. [DOI] [PubMed] [Google Scholar]
  3. Ermolieff J., Lin X., Tang J. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. Biochemistry. 1997 Oct 7;36(40):12364–12370. doi: 10.1021/bi971072e. [DOI] [PubMed] [Google Scholar]
  4. Fujinaga M., Chernaia M. M., Tarasova N. I., Mosimann S. C., James M. N. Crystal structure of human pepsin and its complex with pepstatin. Protein Sci. 1995 May;4(5):960–972. doi: 10.1002/pro.5560040516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Graves M. C., Lim J. J., Heimer E. P., Kramer R. A. An 11-kDa form of human immunodeficiency virus protease expressed in Escherichia coli is sufficient for enzymatic activity. Proc Natl Acad Sci U S A. 1988 Apr;85(8):2449–2453. doi: 10.1073/pnas.85.8.2449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hansen J., Billich S., Schulze T., Sukrow S., Moelling K. Partial purification and substrate analysis of bacterially expressed HIV protease by means of monoclonal antibody. EMBO J. 1988 Jun;7(6):1785–1791. doi: 10.1002/j.1460-2075.1988.tb03009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hong L., Treharne A., Hartsuck J. A., Foundling S., Tang J. Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases. Biochemistry. 1996 Aug 20;35(33):10627–10633. doi: 10.1021/bi960481s. [DOI] [PubMed] [Google Scholar]
  8. Ido E., Han H. P., Kezdy F. J., Tang J. Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S. J Biol Chem. 1991 Dec 25;266(36):24359–24366. [PubMed] [Google Scholar]
  9. Lapatto R., Blundell T., Hemmings A., Overington J., Wilderspin A., Wood S., Merson J. R., Whittle P. J., Danley D. E., Geoghegan K. F. X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes. Nature. 1989 Nov 16;342(6247):299–302. doi: 10.1038/342299a0. [DOI] [PubMed] [Google Scholar]
  10. Lin Y., Fusek M., Lin X., Hartsuck J. A., Kezdy F. J., Tang J. pH dependence of kinetic parameters of pepsin, rhizopuspepsin, and their active-site hydrogen bond mutants. J Biol Chem. 1992 Sep 15;267(26):18413–18418. [PubMed] [Google Scholar]
  11. Navia M. A., Fitzgerald P. M., McKeever B. M., Leu C. T., Heimbach J. C., Herber W. K., Sigal I. S., Darke P. L., Springer J. P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature. 1989 Feb 16;337(6208):615–620. doi: 10.1038/337615a0. [DOI] [PubMed] [Google Scholar]
  12. Poorman R. A., Tomasselli A. G., Heinrikson R. L., Kézdy F. J. A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. J Biol Chem. 1991 Aug 5;266(22):14554–14561. [PubMed] [Google Scholar]
  13. Ridky T. W., Cameron C. E., Cameron J., Leis J., Copeland T., Wlodawer A., Weber I. T., Harrison R. W. Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme subsites. J Biol Chem. 1996 Mar 1;271(9):4709–4717. doi: 10.1074/jbc.271.9.4709. [DOI] [PubMed] [Google Scholar]
  14. Sali A., Veerapandian B., Cooper J. B., Moss D. S., Hofmann T., Blundell T. L. Domain flexibility in aspartic proteinases. Proteins. 1992 Feb;12(2):158–170. doi: 10.1002/prot.340120209. [DOI] [PubMed] [Google Scholar]
  15. Shimada T., Yasuda K., Mori A., Ni H., Mercado-Asis L. B., Murase H., Miura K. Aldosterone binding to mineralocorticoid receptors of mononuclear leukocytes in diabetic subjects. Acta Endocrinol (Copenh) 1993 Jun;128(6):529–535. doi: 10.1530/acta.0.1280529. [DOI] [PubMed] [Google Scholar]
  16. Silva A. M., Cachau R. E., Sham H. L., Erickson J. W. Inhibition and catalytic mechanism of HIV-1 aspartic protease. J Mol Biol. 1996 Jan 19;255(2):321–346. doi: 10.1006/jmbi.1996.0026. [DOI] [PubMed] [Google Scholar]
  17. Suguna K., Bott R. R., Padlan E. A., Subramanian E., Sheriff S., Cohen G. H., Davies D. R. Structure and refinement at 1.8 A resolution of the aspartic proteinase from Rhizopus chinensis. J Mol Biol. 1987 Aug 20;196(4):877–900. doi: 10.1016/0022-2836(87)90411-6. [DOI] [PubMed] [Google Scholar]
  18. Vance J. E., LeBlanc D. A., London R. E. Cleavage of the X-Pro peptide bond by pepsin is specific for the trans isomer. Biochemistry. 1997 Oct 28;36(43):13232–13240. doi: 10.1021/bi970918b. [DOI] [PubMed] [Google Scholar]
  19. Wlodawer A., Erickson J. W. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem. 1993;62:543–585. doi: 10.1146/annurev.bi.62.070193.002551. [DOI] [PubMed] [Google Scholar]
  20. Wlodawer A., Miller M., Jaskólski M., Sathyanarayana B. K., Baldwin E., Weber I. T., Selk L. M., Clawson L., Schneider J., Kent S. B. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science. 1989 Aug 11;245(4918):616–621. doi: 10.1126/science.2548279. [DOI] [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES